Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy

AXL overexpression is a common resistance mechanism to anticancer therapies, including the resistance to BYL719 (Alpelisib) — the p110α isoform specific inhibitor of phosphoinositide 3-kinase (PI3K) — in esophagus squamous cell carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC). Howe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCI Insight
Autors principals: Badarni, Mai, Prasad, Manu, Balaban, Noa, Zorea, Jonathan, Yegodayev, Ksenia M., Joshua, Ben-Zion, Dinur, Anat Bahat, Grénman, Reidar, Rotblat, Barak, Cohen, Limor, Elkabets, Moshe
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538319/
https://ncbi.nlm.nih.gov/pubmed/30860495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.125341
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars